NASDAQ:NYMX - Nymox Pharmaceutical Stock Price, Price Target & More

Get Started

$3.72 -0.06 (-1.59 %)

(As of 05/25/2018 03:13 AM ET)

Previous Close$3.78

Today's Range$3.60 - $3.79

52-Week Range$3.00 - $4.69

Volume100,700 shs

Average Volume155,919 shs

Market Capitalization$215.67 million

P/E RatioN/A

Dividend YieldN/A

Beta0.75

About Nymox Pharmaceutical (NASDAQ:NYMX)

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.

Receive NYMX News and Ratings via Email

Sign-up to receive the latest news and ratings for NYMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:NYMX

CUSIPN/A

Webwww.nymox.com

Phone800-936-9669

Debt

Debt-to-Equity RatioN/A

Current Ratio0.47

Quick Ratio0.46

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$220,000.00

Price / Sales967.37

Cash FlowN/A

Price / CashN/A

Book Value($0.02) per share

Price / Book-186.00

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-13,420,000.00

Net Margins-4,403.32%

Return on EquityN/A

Return on Assets-1,053.89%

Miscellaneous

Employees6

Outstanding Shares57,210,000

Nymox Pharmaceutical (NASDAQ:NYMX) Frequently Asked Questions

What is Nymox Pharmaceutical's stock symbol?

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

How were Nymox Pharmaceutical's earnings last quarter?

Nymox Pharmaceutical (NASDAQ:NYMX) posted its quarterly earnings data on Friday, November, 14th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter. The biopharmaceutical company earned $0.08 million during the quarter. View Nymox Pharmaceutical's Earnings History.

When is Nymox Pharmaceutical's next earnings date?

Nymox Pharmaceutical is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Nymox Pharmaceutical.

Who are some of Nymox Pharmaceutical's key competitors?

Some companies that are related to Nymox Pharmaceutical include Meridian Bioscience (VIVO), New England Nuclear (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Vermillion (VRML), Akers Biosciences (AKER), ImmuCell (ICCC), Achieve Life Sciences (ACHV), GeneNews (GNWSF), ARCA biopharma (ABIO), FluoroPharma Medical (FPMI) and BG Medicine (BGMD).

Who are Nymox Pharmaceutical's key executives?

Nymox Pharmaceutical's management team includes the folowing people:

Dr. Paul Averback, Founder, Chairman, CEO & Pres (Age 67)
Mr. Erik Danielsen, Chief Financial Officer (Age 55)
Mr. Randall J. Lanham, Gen. Counsel, Sec. & Director (Age 54)
Dr. Judith Fitzpatrick Ph.D., Exec. (Age 69)
Dr. Suresh Kalbag M.D., Director of CMC Operations

Has Nymox Pharmaceutical been receiving favorable news coverage?

Press coverage about NYMX stock has been trending somewhat positive recently, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Nymox Pharmaceutical earned a media sentiment score of 0.04 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 46.55 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Nymox Pharmaceutical's major shareholders?

Nymox Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.31%) and Wedbush Securities Inc. (0.43%). View Institutional Ownership Trends for Nymox Pharmaceutical.

Which institutional investors are selling Nymox Pharmaceutical stock?

NYMX stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Nymox Pharmaceutical.

Which institutional investors are buying Nymox Pharmaceutical stock?

NYMX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc.. View Insider Buying and Selling for Nymox Pharmaceutical.

How do I buy shares of Nymox Pharmaceutical?

Shares of NYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nymox Pharmaceutical's stock price today?

One share of NYMX stock can currently be purchased for approximately $3.72.

How big of a company is Nymox Pharmaceutical?

Nymox Pharmaceutical has a market capitalization of $215.67 million and generates $220,000.00 in revenue each year. Nymox Pharmaceutical employs 6 workers across the globe.

How can I contact Nymox Pharmaceutical?

Nymox Pharmaceutical's mailing address is 9900 CAVENDISH BLVD. SUITE 306, St.-Laurent A8, H4M 2V2. The biopharmaceutical company can be reached via phone at 800-936-9669 or via email at [email protected]

MarketBeat Community Rating for Nymox Pharmaceutical (NYMX)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		71 (Vote Outperform)
Underperform Votes:		67 (Vote Underperform)
Total Votes:		138

MarketBeat's community ratings are surveys of what our community members think about Nymox Pharmaceutical and other stocks. Vote "Outperform" if you believe NYMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NYMX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Nymox Pharmaceutical (NASDAQ:NYMX) Analyst Ratings History

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details

(Data available from 5/25/2016 forward)

Nymox Pharmaceutical (NASDAQ:NYMX) Earnings History and Estimates Chart

Earnings by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)

Nymox Pharmaceutical (NASDAQ NYMX) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/6/2018
8/7/2017	Q2 2017		($0.05)		$0.01 million	View	N/A
5/15/2017	Q1 2017		($0.06)		$0.08 million	View	N/A
3/31/2017	Q4 2016		($0.06)		$0.04 million	View	N/A
11/15/2016	Q3 2016		($0.07)		$0.05 million	View	N/A
8/22/2016	Q2 2016		($0.08)		$0.15 million	View	N/A
5/16/2016	Q1 2016		($0.07)		$0.04 million	View	N/A
3/30/2016	Q4 2015		($0.10)		$0.08 million	View	N/A
12/31/2015	Q3 2015		($0.26)		$0.05 million	View	N/A
8/24/2015	Q2 2015		($0.63)		$0.06 million	View	N/A
5/15/2015	Q1 2015		$0.04		$0.08 million	View	N/A
3/31/2015	Q4 2014		($0.01)		$0.08 million	View	N/A
11/14/2014	Q314		($0.02)		$0.08 million	View	N/A
8/11/2014	Q2 2014		($0.02)		$0.10 million	View	N/A
5/15/2014	Q1 2014		($0.07)		$0.08 million	View	N/A
3/14/2014	Q4 2013		($0.03)		$0.94 million	View	N/A
11/13/2013	Q3		($0.03)		$0.74 million	View	N/A
8/14/2013	Q2 2013		($0.04)		$0.19 million	View	N/A
5/15/2013	Q1 2013	($0.05)	($0.03)	$0.78 million	$0.1843 million	View	N/A
3/15/2013	Q4 2012	($0.05)	($0.08)			View	N/A
11/14/2012	Q312	($0.06)	($0.04)			View	N/A
8/14/2012	Q2 2012	($0.06)	($0.05)			View	N/A
5/15/2012	Q1 2012	($0.06)	($0.06)			View	N/A
3/15/2012	Q4 2011	($0.06)	($0.06)			View	N/A
11/14/2011	Q3 2011	($0.05)	($0.05)			View	N/A
8/12/2011	Q2 2011	($0.04)	($0.06)			View	N/A
5/13/2011	Q1 2011	($0.05)	($0.14)			View	N/A
3/15/2011	Q4 2010	($0.05)	($0.07)			View	N/A
11/12/2010	Q3 2010		($0.05)			View	N/A
8/13/2010	Q2 2010		($0.05)			View	N/A
5/14/2010	Q1 2010		($0.04)			View	N/A
3/11/2010	Q4 2009		($0.05)			View	N/A
11/13/2009	Q3 2009		($0.04)			View	N/A
8/14/2009	Q2 2009		($0.04)			View	N/A
5/15/2009	Q1 2009		($0.03)			View	N/A
11/14/2008	Q3 2008		($0.05)			View	N/A
8/13/2008	Q2 2008		($0.04)			View	N/A
5/14/2008	Q1 2008		($0.04)			View	N/A
3/14/2008	Q4 2007		($0.04)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Nymox Pharmaceutical (NASDAQ:NYMX) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Nymox Pharmaceutical (NASDAQ NYMX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 54.00%
Institutional Ownership Percentage: 6.05%

Insider Trading History for Nymox Pharmaceutical (NASDAQ:NYMX)

Institutional Ownership by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)

Nymox Pharmaceutical (NASDAQ NYMX) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/26/2018	James George Robinson	Director	Buy	8,000	$3.93	$31,440.00	3,159,550
3/20/2018	James George Robinson	Director	Buy	8,000	$4.02	$32,160.00	3,152,550
3/15/2018	James George Robinson	Director	Buy	8,000	$3.58	$28,640.00	3,144,550
3/9/2018	James George Robinson	Director	Buy	8,000	$3.48	$27,840.00	3,136,550
2/21/2018	James George Robinson	Director	Buy	6,000	$3.23	$19,380.00	3,123,250
2/16/2018	James George Robinson	Director	Buy	7,000	$3.27	$22,890.00
2/12/2018	James George Robinson	Director	Buy	8,000	$3.27	$26,160.00	3,107,850
2/8/2018	James George Robinson	Director	Buy	10,000	$3.37	$33,700.00	3,091,050
2/2/2018	James George Robinson	Director	Buy	5,000	$3.47	$17,350.00	3,090,550
1/18/2018	James George Robinson	Director	Buy	3,000	$3.14	$9,420.00	3,085,550
8/3/2017	James George Robinson	Director	Buy	10,000	$3.73	$37,300.00	3,077,550
8/2/2017	James George Robinson	Director	Buy	5,000	$3.79	$18,950.00	3,077,550
8/1/2017	James George Robinson	Director	Buy	15,000	$3.72	$55,800.00	3,062,550
7/7/2017	James George Robinson	Director	Buy	11,500	$4.00	$46,000.00	3,046,550
7/6/2017	James George Robinson	Director	Buy	3,000	$3.92	$11,760.00	3,046,550
7/5/2017	James George Robinson	Director	Buy	5,000	$3.97	$19,850.00	3,046,550
6/28/2017	James George Robinson	Director	Buy	8,500	$4.09	$34,765.00	3,040,050
6/26/2017	James George Robinson	Director	Buy	15,000	$3.80	$57,000.00	3,027,550
6/21/2017	James George Robinson	Director	Buy	15,000	$3.77	$56,550.00	3,008,150
6/20/2017	James George Robinson	Director	Buy	5,000	$3.76	$18,800.00	3,008,150
6/19/2017	James George Robinson	Director	Buy	5,000	$3.79	$18,950.00	3,008,150
5/30/2017	James George Robinson	Director	Buy	54,500	$3.81	$207,645.00	2,957,550
3/8/2017	James George Robinson	Director	Buy	50,000	$3.59	$179,500.00	2,906,078
8/10/2016	James George Robinson	Director	Buy	500	$2.47	$1,235.00	2,907,550
8/4/2016	James George Robinson	Director	Buy	7,000	$3.41	$23,870.00	2,902,550
7/29/2016	James George Robinson	Director	Buy	22,500	$3.86	$86,850.00	2,880,050
7/20/2016	James George Robinson	Director	Buy	10,000	$3.33	$33,300.00	2,870,050
7/7/2016	James George Robinson	Director	Buy	20,000	$3.28	$65,600.00	2,850,050
6/29/2016	James George Robinson	Director	Buy	17,500	$3.53	$61,775.00	2,833,050
6/24/2016	James George Robinson	Director	Buy	22,500	$2.97	$66,825.00	2,810,050
5/13/2016	James George Robinson	Director	Buy	28,010	$2.31	$64,703.10	2,782,550
5/3/2016	James George Robinson	Director	Buy	6,990	$2.36	$16,496.40	2,777,050
4/29/2016	James George Robinson	Director	Buy	15,000	$2.27	$34,050.00	2,762,550
4/15/2016	James George Robinson	Director	Buy	39,500	$2.39	$94,405.00	2,722,550
4/1/2016	James George Robinson	Director	Buy	20,500	$2.40	$49,200.00	2,701,050
3/24/2016	James George Robinson	Director	Buy	40,000	$2.29	$91,600.00	2,659,050
1/12/2016	James George Robinson	Director	Buy	20,000	$2.44	$48,800.00	2,657,550
1/8/2016	James George Robinson	Director	Buy	95,000	$2.90	$275,500.00	2,637,550
12/30/2015	James George Robinson	Director	Buy	5,000	$3.38	$16,900.00	2,542,550
12/29/2015	James George Robinson	Director	Buy	14,000	$3.55	$49,700.00	2,542,550
12/28/2015	James George Robinson	Director	Buy	6,000	$3.79	$22,740.00	2,542,550
12/23/2015	James George Robinson	Director	Buy	29,854	$3.54	$105,683.16	2,517,550
12/18/2015	James George Robinson	Director	Buy	63,334	$3.56	$225,469.04	2,487,696
12/11/2015	James George Robinson	Director	Buy	46,812	$3.51	$164,310.12	2,424,362
12/4/2015	James George Robinson	Director	Buy	110,000	$3.44	$378,400.00	2,377,550
9/3/2015	James George Robinson	Director	Buy	100,000	$2.25	$225,000.00	2,267,550

(Data available from 1/1/2013 forward)

Nymox Pharmaceutical (NASDAQ NYMX) News Headlines

Source:

Date	Headline
	Fexapotide Triflutate Pivotal Phase 3 Study Results Presented and Discussed at American Urological Association ... globenewswire.com - May 23 at 4:35 PM
	Nymox Pharma (NYMX) Highlights Fexapotide Triflutate Pivotal Phase 3 Study Results www.streetinsider.com - May 23 at 4:35 PM
	Fexapotide Triflutate Pivotal Phase 3 Study Results Presented and Discussed at American Urological Association Annual Meeting in San Francisco finance.yahoo.com - May 22 at 4:24 PM
	Nymox: 1Q Earnings Snapshot finance.yahoo.com - May 16 at 9:44 AM
	Nymox Pharmaceutical (NYMX) versus Oxford Immunotec Global (OXFD) Head-To-Head Review www.americanbankingnews.com - May 8 at 5:21 PM
	Contrasting Nymox Pharmaceutical (NYMX) & Myriad Genetics (MYGN) www.americanbankingnews.com - May 6 at 1:25 PM
	Quidel (QDEL) versus Nymox Pharmaceutical (NYMX) Head-To-Head Comparison www.americanbankingnews.com - May 3 at 12:33 PM
	What You Must Know About Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) Major Investors finance.yahoo.com - May 1 at 4:23 PM
	Nymox Pharmaceutical (NYMX) versus Oxford Immunotec Global (OXFD) Head to Head Comparison www.americanbankingnews.com - April 28 at 11:20 AM
	Analyzing Nymox Pharmaceutical (NYMX) and Quotient (QTNT) www.americanbankingnews.com - April 23 at 9:20 PM
	Quidel (QDEL) versus Nymox Pharmaceutical (NYMX) Head-To-Head Analysis www.americanbankingnews.com - April 23 at 1:28 PM
	Head to Head Survey: Celldex Therapeutics (CLDX) and Nymox Pharmaceutical (NYMX) www.americanbankingnews.com - April 20 at 3:34 PM
	Nymox Pharmaceutical (NYMX) Cut to Sell at ValuEngine www.americanbankingnews.com - April 20 at 1:19 PM
	Nymox Pharmaceutical (NYMX) Stock Rating Lowered by ValuEngine www.americanbankingnews.com - April 16 at 7:35 PM
	Analyzing BG Medicine (BGMD) and Nymox Pharmaceutical (NYMX) www.americanbankingnews.com - April 16 at 9:27 AM
	Should You Worry About Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) CEO Pay? finance.yahoo.com - April 14 at 9:37 AM
	Nymox secures $16.25M capital raise seekingalpha.com - April 12 at 4:26 PM
	Nymox Pharma (NYMX) Reports $16.25 Million Equity Financing With Qualified Long-Term Investors www.streetinsider.com - April 12 at 4:26 PM
	Nymox Announces $16.25 Million Equity Financing With Qualified Long-Term Investors finance.yahoo.com - April 12 at 10:22 AM
	Nymox Pharmaceutical (NYMX) Upgraded at ValuEngine www.americanbankingnews.com - April 10 at 7:51 PM
	New Online Commentary in UroToday on Fexapotide BPH Clinical Trial Results Publication in World Journal of Urology finance.yahoo.com - April 10 at 4:27 PM
	Contrasting Nymox Pharmaceutical (NYMX) & Immunomedics (IMMU) www.americanbankingnews.com - April 4 at 11:20 AM
	Nymox Pharmaceutical (NYMX) vs. Lantheus (LNTH) Critical Review www.americanbankingnews.com - April 3 at 7:17 PM
	Nymox Pharmaceutical Co. (NYMX) Director James George Robinson Acquires 8,000 Shares www.americanbankingnews.com - March 27 at 10:50 PM
	James George Robinson Purchases 8,000 Shares of Nymox Pharmaceutical Co. (NYMX) Stock www.americanbankingnews.com - March 22 at 8:13 PM
	Should You Have Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) In Your Portfolio? finance.yahoo.com - March 19 at 4:20 PM
	Nymox Pharmaceutical Co. (NYMX) Director James George Robinson Buys 8,000 Shares www.americanbankingnews.com - March 16 at 1:55 PM
	Symposium and Panel Discussion on Nymox's Fexapotide To Be Held at American Urological Association Mid-Atlantic Section Annual Meeting on March 3 finance.yahoo.com - March 1 at 4:48 PM
	Interested In Nymox Pharmaceutical Corporation (NASDAQ:NYMX)? Here’s What Its Recent Performance Looks Like finance.yahoo.com - February 28 at 9:25 AM
	James George Robinson Purchases 6,000 Shares of Nymox Pharmaceutical Co. (NYMX) Stock www.americanbankingnews.com - February 23 at 12:50 PM
	Nymox Pharmaceutical Co. (NYMX) Director James George Robinson Buys 7,000 Shares www.americanbankingnews.com - February 20 at 7:50 PM
	Nymox Pharmaceutical Co. (NYMX) Director James George Robinson Buys 10,000 Shares www.americanbankingnews.com - February 9 at 6:34 PM
	Nymox Pharmaceutical Co. (NYMX) Director Acquires $17,350.00 in Stock www.americanbankingnews.com - February 6 at 7:00 PM
	Nymox Announces US NDA for Fexapotide for BPH - GlobeNewswire (press release) globenewswire.com - February 6 at 9:06 AM
	Nymox Announces US NDA for Fexapotide for BPH finance.yahoo.com - February 5 at 4:25 PM
	The Clock Is Ticking For Nymox Pharma's European Drug Application - Bet On A Rejection - Seeking Alpha seekingalpha.com - February 2 at 9:08 AM
	Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology finance.yahoo.com - January 30 at 9:33 AM
	Nymox Pharma (NYMX) Announces 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate in 146 U.S. Men www.streetinsider.com - January 23 at 4:06 PM
	Nymox Pharma (NYMX) Announces 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study ... - StreetInsider.com www.streetinsider.com - January 23 at 8:19 AM
	AMGN's LIBERTY Meets Goals, ANTH Yields RESULT, CCXI Up On Cancer Trial Data - Nasdaq www.nasdaq.com - January 23 at 8:19 AM
	Nymox Reports 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate in 146 U.S. Men finance.yahoo.com - January 22 at 5:50 PM
	ETFs with exposure to Nymox Pharmaceutical Corp. : December 22, 2017 finance.yahoo.com - December 22 at 7:31 PM
	ETFs with exposure to Nymox Pharmaceutical Corp. : December 11, 2017 finance.yahoo.com - December 11 at 4:44 PM
	ETFs with exposure to Nymox Pharmaceutical Corp. : November 30, 2017 finance.yahoo.com - November 30 at 4:34 PM
	Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 finance.yahoo.com - November 29 at 10:25 AM
	Nymox Fexapotide Symposium and Panel Discussion at American ... - GlobeNewswire (press release) globenewswire.com - November 27 at 4:43 PM
	Symposium and Panel Discussion on Nymox's Fexapotide To Be Held at American Urological Association www.nasdaq.com - November 12 at 11:14 AM
	Symposium and Panel Discussion on Nymox's Fexapotide To Be Held at American Urological Association North ... globenewswire.com - November 12 at 11:14 AM
	Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological ... - Nasdaq www.nasdaq.com - November 9 at 7:56 AM
	Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association ... globenewswire.com - November 7 at 4:34 PM

Nymox Pharmaceutical (NASDAQ:NYMX) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Nymox Pharmaceutical (NASDAQ:NYMX) Income Statement, Balance Sheet and Cash Flow Statement

Nymox Pharmaceutical (NASDAQ NYMX) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff